查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014828

體外診斷品管市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

In-Vitro Diagnostics Quality Control Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，體外診斷品管市場價值將達到 16.1 億美元，到 2026 年將成長至 17.4 億美元，到 2032 年將達到 28.8 億美元，複合年成長率為 8.67%。

主要市場統計數據
基準年 2025 16.1億美元
預計年份：2026年 17.4億美元
預測年份：2032年 28.8億美元
複合年成長率 (%) 8.67%

在技​​術融合、監管和日益複雜的營運環境下，品管正成為臨床檢查室。

本文將體外診斷品管定位為現代臨床檢查室運作的基石，對病人安全、法規遵循以及臨床決策的可靠性至關重要。分析平台的進步、複雜分子檢測的激增以及診斷在個人化醫療中日益重要的作用，都凸顯了健全的品管系統的重要性。隨著檢查室和製造商努力實現儀器、試劑和數據系統性能的協調一致，展現出一致的準確性和精密度比以往任何時候都更加關鍵。

快速的技術、數位化和監管變革如何重塑診斷領域的品管實踐以及供應商檢查室之間的合作？

在創新、數位化和不斷變化的監管環境的交匯點上，體外診斷的品管環境正在加速變革。新興的儀器平台實現了更高的通量和自動化程度，從而對更精密的品管和試劑配方提出了更高的要求，以檢驗擴展的動態範圍。隨著硬體的進步，資料管理和品質保證軟體解決方案也在日趨成熟，實現了即時監控和預測分析，從而改變了檢查室處理過程控制和偏差管理的方式。

評估 2025 年美國關稅變化對診斷藥物品管的供應鏈韌性、籌資策略和營運連續性的影響。

2025年實施的新關稅對體外診斷試劑的品管相關的供應鏈、籌資策略和產品成本結構產生了切實的影響。依賴跨境生產和零件採購的分析儀器、品管樣品、試劑和專用軟體供應商正在調整其物流和定價模式，以緩解利潤壓力並維持交貨可靠性。為此，採購部門和檢查室經理正在重新審視供應商多元化和庫存策略，以確保關鍵品管材料和試劑的持續供應。

將產品類型、技術、應用和最終用戶趨勢與營運重點和供應商策略聯繫起來的全面細分洞察。

深入分析揭示了不同產品、技術、應用和最終用戶類別中存在的細微價值提案和營運要求差異，因此供應商和檢查室需要製定個人化的策略。依產品類型分類，分析儀器和設備需要專注於系統互通性和維護工作流程。自動化系統可提高處理能力，而半自動化系統則可實現靈活的小規模部署。品管產品必須滿足穩定性和基質相容性要求；液體品控品可立即使用，而冷凍乾燥品控品則需要長期儲存。品管(QC) 試劑需要在不同平台上均具備檢驗的性能。此外，從資料管理系統和實驗室資訊管理系統到專用品質控制軟體，各種軟體解決方案在確保結果一致性和可追溯性方面正發揮越來越重要的作用，以滿足審計要求。

美洲、歐洲、中東、非洲和亞太地區品管解決方案的採購、驗證和實施的區域趨勢及實際影響

區域趨勢影響品管解決方案的採購決策、監管方式和實施管道，而各區域的促進因素和限制因素又各不相同。在美洲，人們高度重視整合檢驗網路，並投資於自動化和數位化品管工具，以滿足對快速週轉和監管可追溯性的期望。相較之下，歐洲、中東和非洲的管理體制和基礎設施成熟度則呈現出多樣化的特點，既有採用高度複雜管理系統的集中式參考檢查室，也有優先考慮成本效益高、穩健可靠且適用於分散式環境的可攜式解決方案的小規模機構。

主要企業如何調整其綜合產品系列、服務產品和策略夥伴關係關係，以重新定義其在品管的競爭優勢？

體外診斷品管領域的主要企業正尋求在技術創新、策略夥伴關係和服務差異化之間取得平衡，以確保與客戶建立長期合作關係。市場領導者強調提供整合解決方案，將校準的品管品、相容的試劑和雲端軟體結合，從而實現無縫的檢驗工作流程和可審計的報告。與儀器製造商和臨床檢查室建立策略合作夥伴關係也十分普遍，這有助於共同開發針對特定平台性能特徵的品管品，並加速檢查室部署。

永續診斷品管中採用的實際優先事項，旨在加強供應鏈韌性、互通性、人力資源能力和驗證支援。

向行業領導者提出的切實可行的建議側重於加強供應鏈韌性、提高互通性以及投資人力資源能力，以維持高品質的診斷結果。製造商應優先考慮模組化設計和跨平台檢驗，以減少相容性障礙並簡化檢查室採購決策。此外，提高批次追溯和生產來源的透明度將有助於滿足監管要求並建立臨床客戶的信任。這些措施應輔以可擴展的服務模式，包括檢驗支援、培訓和遠端監控，從而縮短檢查室團隊掌握相關技術所需的時間。

為了確保我們的品管結果在實踐和技術上的有效性，我們採用了嚴格的混合方法，結合了訪談、標準分析和三角驗證的證據。

本調查方法結合了原始定性資料、二手文獻綜述以及技術和法規資訊來源的結構化整合，以全面評估品管趨勢。原始數據包括對實驗室經理、品管和產品經理的訪談，以了解營運挑戰、驗證實踐和採購考量，並透過諮詢法規專家來補充對指南和實施趨勢的解讀。二級資訊來源包括同行評審文獻、標準文件和公開的法規文件，這些文件描述了控制設計和驗證的技術基礎。

投資於互通性人才和供應鏈透明度將塑造未來診斷醫療設備品管的可靠性和合規性的原因概述。

總之，維護和推廣體外診斷品管實踐是一項策略性挑戰，它支撐著臨床可靠性和法規遵循。在技​​術創新、對分子診斷和免疫檢測日益成長的依賴以及對數據可追溯性和供應鏈透明度的不斷提高的期望的驅動下，該領域正經歷著快速轉型。這些因素既帶來了挑戰，也帶來了機會。挑戰包括協調不同平台的性能並確保穩健的供應鏈，而機會則包括利用數位化工具、模組化管理產品和合作夥伴關係來簡化驗證和監控流程。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：體外診斷試劑品管市場：依產品類型分類

  • 分析儀/設備
    • 自動化系統
    • 半自動系統
  • 標準材料
  • 品控試劑
    • 液體控制
    • 凍乾控制
  • 軟體解決方案
    • 資料管理系統
    • LIMS
    • 品質控制軟體

第9章：體外診斷試劑品管市場：依技術分類

  • 臨床化學
    • 比色法
    • 濁度檢測法
  • 血液學
    • 自動血球計數器
    • 流式細胞技術
  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 螢光免疫分析
  • 微生物學
    • 文化
    • PCR
  • 分子診斷
    • 下一代定序
    • PCR

第10章 體外診斷試劑品管市場：依應用領域分類

  • 循環系統
    • 心臟標記檢測
    • 就地檢驗
  • 基因檢測
    • 攜帶者篩檢
    • 產前檢查
  • 傳染病檢查
    • 細菌檢測
    • 病毒檢測
  • 腫瘤學
    • 微量殘存疾病
    • 腫瘤標記檢測
  • 毒理學
    • 濫用藥物
    • 治療監測

第11章 體外診斷試劑品管市場：依最終用戶分類

  • 血庫
    • 國家血庫
    • 區域血庫
  • 診斷實驗室
    • 醫院檢查室
    • 獨立檢測實驗室
  • 醫院和診所
    • 臨床檢查室
    • 參考檢測實驗室
  • 研究機構
    • 學術機構
    • 私人實驗室

第12章 體外診斷試劑品管市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 體外診斷試劑品管市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 體外診斷試劑品管市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國體外診斷試劑品管市場

第16章：中國體外診斷試劑品管市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Grifols, SA
  • Microbix Biosystems Inc.
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • Roche Holding AG
  • Seracare Life Sciences, Inc.
  • Siemens Healthineers AG
  • Sun Diagnostics, LLC
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
  • ZeptoMetrix LLC
Product Code: MRR-43127F7279E1

The In-Vitro Diagnostics Quality Control Market was valued at USD 1.61 billion in 2025 and is projected to grow to USD 1.74 billion in 2026, with a CAGR of 8.67%, reaching USD 2.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.74 billion
Forecast Year [2032] USD 2.88 billion
CAGR (%) 8.67%

Positioning quality control as a foundational necessity in clinical laboratories amid technological convergence regulatory scrutiny and operational complexity

The introduction frames in-vitro diagnostics quality control as an indispensable pillar of modern clinical laboratory operations, integral to patient safety, regulatory compliance, and the reliability of clinical decision-making. Advances in analytical platforms, the proliferation of complex molecular assays, and the expanding role of diagnostics in personalized medicine have collectively elevated the importance of robust quality control regimes. As laboratories and manufacturers seek to harmonize performance across instruments, reagents, and data systems, the ability to demonstrate consistent accuracy and precision has never been more critical.

This section situates current developments within a broader context of technological convergence and heightened regulatory scrutiny. It highlights the interplay between instrumentation, control materials, and software in creating closed-loop quality management ecosystems. Moreover, it underscores how laboratory leaders and manufacturers are adapting to tighter traceability requirements and expectations for integrated data management. The narrative transitions to a recognition of the sector's operational challenges, including workforce skills gaps, supply chain complexity, and the need for standardized performance metrics, setting the stage for the more detailed analyses that follow.

How rapid technological, digital, and regulatory shifts are reshaping quality control practices and vendor-laboratory collaboration in diagnostics

Transformative shifts in the in-vitro diagnostics quality control landscape are accelerating as innovation, digitalization, and regulatory evolution intersect. Emerging instrumentation platforms are delivering higher throughput and greater automation, which in turn demand more sophisticated control materials and reagent formulations to validate expanded dynamic ranges. Parallel to hardware advancement, software solutions for data management and quality assurance are maturing, enabling real-time monitoring and predictive analytics that change how laboratories approach process control and deviation management.

At the same time, the ascendancy of molecular diagnostics and immunoassays, accompanied by the proliferation of point-of-care testing, has diversified the types of controls needed to assure result integrity across settings. This diversification compels manufacturers and laboratories to rethink compatibility, calibration strategies, and cross-platform equivalence. Regulatory authorities are responding with more detailed guidance on validation and post-market surveillance, prompting stakeholders to integrate regulatory intelligence into product development lifecycles. Together, these shifts are reshaping procurement priorities, vendor relationships, and the skills required of laboratory personnel, driving a transition toward more collaborative and technology-enabled quality ecosystems.

Evaluating how 2025 United States tariff changes have influenced supply chain resilience, procurement strategy, and operational continuity for diagnostics quality control

The introduction of new tariffs in the United States during 2025 has introduced tangible ripple effects across supply chains, procurement strategies, and product cost structures relevant to quality control in in-vitro diagnostics. Suppliers of analyzers, control materials, reagents, and specialized software that rely on cross-border manufacturing and component sourcing are adjusting logistics and pricing models to mitigate margin pressure and maintain delivery reliability. In response, purchasing organizations and laboratory managers are reassessing supplier diversification and inventory strategies to preserve continuity of critical control materials and reagents.

Operationally, some manufacturers are accelerating efforts to localize production steps, redesign packaging for cost-efficiency, and reconfigure sourcing to minimize tariff exposure. These actions can improve resilience but may also introduce variability in lead times and qualification requirements as new production lines or alternative suppliers are validated. Importantly, the tariffs have underscored the value of transparent supplier data and traceability, reinforcing the need for rigorous lot-to-lot verification programs and comprehensive documentation. Collectively, these developments are prompting a reexamination of total cost of ownership and risk management practices, with stakeholders prioritizing strategic partnerships and supply chain visibility to maintain uninterrupted quality control operations.

Comprehensive segmentation insights tying product types technologies applications and end-user dynamics to operational priorities and supplier strategies

Segmentation-driven insights reveal nuanced value propositions and operational imperatives across product, technology, application, and end-user categories, each demanding tailored strategies from suppliers and laboratories. Based on product type, analyzers and instruments require attention to system interoperability and maintenance workflows, where automated systems drive throughput while semi-automated systems offer flexible, lower-volume deployment; control materials must satisfy stability and matrix-matching expectations, with liquid controls providing ready-to-use convenience and lyophilized controls offering extended shelf life; QC reagents call for validated performance across platforms; and software solutions spanning data management systems, laboratory information management systems, and dedicated QC software are increasingly central to harmonizing results and enabling audit-ready traceability.

From a technology perspective, clinical chemistry assays span colorimetric and turbidimetric modalities that place distinct demands on reagent presentation and calibration; hematology follows a split between automated cell counters and flow cytometry, influencing control complexity and verification protocols; immunoassays encompass chemiluminescence, ELISA, and fluorescence formats, each requiring tailored calibrators and interference testing; microbiology workflows differentiate between culture-based approaches and PCR techniques with divergent control needs; and molecular diagnostics-covering next-generation sequencing and PCR-necessitate highly specific controls to validate sensitivity, specificity, and library preparation steps. Application-focused segmentation highlights how cardiology testing emphasizes cardiac marker stability and point-of-care robustness, genetic testing hinges on carrier and prenatal assay accuracy, infectious disease testing requires bacterial and viral detection validation, oncology depends on minimal residual disease and tumor marker fidelity, and toxicology balances drugs of abuse screening with therapeutic drug monitoring precision. End-user segmentation illustrates divergent operational priorities across blood banks, diagnostic laboratories, hospitals and clinics, and research institutes, where national versus regional blood bank operations influence scale and inventory management, hospital-based versus independent laboratories differ in accreditation and workflow integration needs, clinic-level versus reference laboratory services vary in test breadth and turnaround expectations, and academic versus private research institutes balance exploratory assay development with rigorous control validation for publication and translational projects.

Taken together, these segmentation insights suggest that suppliers should prioritize modular product portfolios, validated cross-platform compatibility, and flexible service models, while laboratories should emphasize standardized verification protocols and integrated data strategies to manage complexity and ensure consistent diagnostic performance.

Regional dynamics and practical implications for procurement, validation, and adoption of quality control solutions across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape procurement decisions, regulatory approaches, and adoption pathways for quality control solutions, with each geography presenting distinct drivers and constraints. The Americas exhibit a strong emphasis on consolidation of testing networks and investments in automation and digital quality tools to meet expectations for rapid turnaround and regulatory traceability. In contrast, Europe, the Middle East & Africa present a mosaic of regulatory regimes and infrastructure maturity, leading to a heterogeneous mix of centralized reference laboratories adopting high-complexity control systems and smaller facilities prioritizing cost-effective, robust controls and portable solutions for decentralized settings.

Meanwhile, the Asia-Pacific region is characterized by rapid adoption of novel diagnostic technologies, substantial investments in laboratory modernization, and a diverse supplier landscape that includes both global manufacturers and regionally specialized producers. Cross-regional trends are converging around interoperability, data standardization, and supply chain resilience, but implementation timelines and resource allocation differ substantially. Therefore, international suppliers and laboratory networks must tailor go-to-market approaches and validation packages to accommodate local regulatory frameworks, procurement cycles, and infrastructure capabilities to achieve effective and sustainable quality control integration across regions.

How leading companies are aligning integrated product portfolios service offerings and strategic partnerships to redefine quality control competitiveness

Leading companies in the in-vitro diagnostics quality control space are navigating a balance between technological innovation, strategic partnerships, and service differentiation to secure long-term customer relationships. Market leaders emphasize integrated offerings that combine calibrated control materials, compatible reagents, and cloud-enabled software to deliver seamless verification workflows and audit-ready reporting. Strategic collaborations with instrument manufacturers and clinical laboratories are common, enabling co-development of controls that address platform-specific performance characteristics and accelerate laboratory adoption.

In parallel, several firms are investing in enhanced manufacturing rigor and supply chain transparency to meet the increasing regulatory focus on traceability and lot-level documentation. Service-driven differentiation, such as tailored validation support, remote monitoring, and embedded training programs, is emerging as a critical value-add that reduces adoption friction and strengthens customer retention. Furthermore, smaller specialized players are focusing on niche segments-such as molecular diagnostics controls or point-of-care compatibility-to capitalize on growing assay complexity and unmet validation needs. Collectively, these approaches are reshaping competitive dynamics, with success increasingly tied to the ability to offer end-to-end solutions that align technical performance with practical laboratory workflows and regulatory expectations.

Practical prioritized actions to enhance supply chain resilience interoperability workforce capability and validation support for sustainable diagnostic quality control

Actionable recommendations for industry leaders center on strengthening supply chain resilience, enhancing interoperability, and investing in workforce capabilities to sustain high-quality diagnostics outputs. Manufacturers should prioritize modular design and cross-platform validation to reduce compatibility barriers and simplify procurement decisions for laboratories. In addition, increasing transparency around lot traceability and manufacturing provenance will address regulatory priorities and build trust among clinical customers. These measures should be complemented by scalable service models that include validation support, training, and remote monitoring to reduce time-to-competence for laboratory teams.

Laboratories and health systems should formalize control verification protocols that incorporate robust documentation and leverage advanced data management systems to detect subtle performance shifts. Procurement organizations ought to diversify supplier relationships and incorporate contingency planning into contracts to minimize disruption from geopolitical or tariff-related shocks. Investment in workforce development-particularly in informatics, assay validation, and quality assurance-will be essential to realize the benefits of automation and digital quality tools. Collectively, these recommendations aim to align technical, operational, and commercial priorities to ensure accurate, reliable, and compliant diagnostic results across diverse testing environments.

A rigorous mixed-methods approach combining interviews standards analysis and triangulated evidence to ensure practical and technical relevance in quality control insights

The research methodology combines primary qualitative inputs, secondary literature review, and a structured synthesis of technical and regulatory sources to produce a comprehensive assessment of quality control dynamics. Primary inputs include interviews with laboratory directors, quality managers, and product leaders to capture operational pain points, validation practices, and procurement considerations, supplemented by consultations with regulatory experts to interpret guidance and enforcement trends. Secondary sources comprise peer-reviewed literature, standards documentation, and publicly available regulatory communications that inform the technical underpinnings of control design and validation.

Analytical methods integrate thematic coding of interview data, cross-validation with documented standards, and comparative case analysis to surface patterns in supplier approaches, laboratory workflows, and regional adoption. Care has been taken to triangulate findings across multiple evidence streams, ensuring that conclusions reflect both practical experience and documented requirements. Limitations are acknowledged where proprietary data or nascent technologies constrain full visibility, and recommendations emphasize adaptive strategies that can be refined as new evidence emerges. Overall, the methodology aims to balance technical rigor with practical relevance for stakeholders involved in diagnostics quality control.

Summarizing why interoperability workforce investment and supply chain transparency will determine future reliability and compliance in diagnostics quality control

In conclusion, maintaining and advancing quality control practices in in-vitro diagnostics is a strategic imperative that underpins clinical confidence and regulatory compliance. The sector is experiencing rapid change driven by technological innovation, greater reliance on molecular and immunoassay modalities, and heightened expectations for data traceability and supply chain transparency. These forces are creating both challenges and opportunities: challenges in harmonizing cross-platform performance and securing resilient supply lines, and opportunities in leveraging digital tools, modular control products, and collaborative partnerships to streamline validation and monitoring.

Moving forward, stakeholders who embrace interoperability, invest in workforce capability, and adopt proactive supply chain and validation strategies will be best positioned to ensure consistent diagnostic performance and respond effectively to evolving regulatory requirements. The synthesis presented here offers a framework for prioritizing actions and aligning resources so that laboratories and manufacturers can deliver reliable, patient-centered diagnostic outcomes in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Quality Control Market, by Product Type

  • 8.1. Analyzers & Instruments
    • 8.1.1. Automated Systems
    • 8.1.2. Semi-Automated Systems
  • 8.2. Control Materials
  • 8.3. QC Reagents
    • 8.3.1. Liquid Controls
    • 8.3.2. Lyophilized Controls
  • 8.4. Software Solutions
    • 8.4.1. Data Management Systems
    • 8.4.2. LIMS
    • 8.4.3. QC Software

9. In-Vitro Diagnostics Quality Control Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Colorimetric
    • 9.1.2. Turbidimetric
  • 9.2. Hematology
    • 9.2.1. Automated Cell Counters
    • 9.2.2. Flow Cytometry
  • 9.3. Immunoassay
    • 9.3.1. Chemiluminescence Immunoassay
    • 9.3.2. ELISA
    • 9.3.3. Fluorescence Immunoassay
  • 9.4. Microbiology
    • 9.4.1. Culture
    • 9.4.2. PCR
  • 9.5. Molecular Diagnostics
    • 9.5.1. Next-Generation Sequencing
    • 9.5.2. PCR

10. In-Vitro Diagnostics Quality Control Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Cardiac Marker Testing
    • 10.1.2. Point-Of-Care Testing
  • 10.2. Genetic Testing
    • 10.2.1. Carrier Screening
    • 10.2.2. Prenatal Testing
  • 10.3. Infectious Disease Testing
    • 10.3.1. Bacterial Detection
    • 10.3.2. Viral Detection
  • 10.4. Oncology
    • 10.4.1. Minimal Residual Disease
    • 10.4.2. Tumor Marker Testing
  • 10.5. Toxicology
    • 10.5.1. Drugs Of Abuse
    • 10.5.2. Therapeutic Drug Monitoring

11. In-Vitro Diagnostics Quality Control Market, by End User

  • 11.1. Blood Banks
    • 11.1.1. National Blood Banks
    • 11.1.2. Regional Blood Banks
  • 11.2. Diagnostic Laboratories
    • 11.2.1. Hospital-Based Laboratories
    • 11.2.2. Independent Laboratories
  • 11.3. Hospitals & Clinics
    • 11.3.1. Clinic Laboratories
    • 11.3.2. Reference Laboratories
  • 11.4. Research Institutes
    • 11.4.1. Academic Institutes
    • 11.4.2. Private Research Laboratories

12. In-Vitro Diagnostics Quality Control Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. In-Vitro Diagnostics Quality Control Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. In-Vitro Diagnostics Quality Control Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States In-Vitro Diagnostics Quality Control Market

16. China In-Vitro Diagnostics Quality Control Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. Grifols, S.A.
  • 17.10. Microbix Biosystems Inc.
  • 17.11. QuidelOrtho Corporation
  • 17.12. Randox Laboratories Ltd.
  • 17.13. Roche Holding AG
  • 17.14. Seracare Life Sciences, Inc.
  • 17.15. Siemens Healthineers AG
  • 17.16. Sun Diagnostics, LLC
  • 17.17. Sysmex Corporation
  • 17.18. Thermo Fisher Scientific Inc.
  • 17.19. Werfen, S.A.
  • 17.20. ZeptoMetrix LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DRUGS OF ABUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY THERAPEUTIC DRUG MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NATIONAL BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGIONAL BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BLOOD BANKS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER,